Definium Therapeutics, Inc. (DFTX)Healthcare | Biotechnology | New York, United States | NasdaqGS
23.18 USD
+0.50
(2.205%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★★★ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:44 a.m. EDT
High-conviction short-term momentum play driven by the 'anxiety drug' narrative and strong cash runway, characterized by speculative options flow ignoring valuation metrics to bet on a massive breakout above $25. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.067973 |
| AutoETS | 0.069056 |
| AutoTheta | 0.086056 |
| AutoARIMA | 0.144205 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 19.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.036 |
| Excess Kurtosis | -0.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.211 |
| Market Cap | 2,311,002,624 |
| Forward P/E | -13.43 |
| Beta | 2.56 |
| Website | https://definiumtx.com |
As of April 19, 2026, 12:44 a.m. EDT: Call activity is heavily skewed toward upside, with significant Open Interest (OI) walls at $23, $24, and $25 strikes for the near-term May expiration. Long-term sentiment shows massive leverage to calls held against deep out-of-the-money strikes (e.g., $6 calls in June/July), indicating a high-conviction speculation on substantial upside (100%+) before year-end. Conversely, put positioning for Q3 and Q4 2026 is virtually non-existent, suggesting traders have priced out near-term downside risk. The implied volatility structure supports a bullish gamma exposure scenario.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.9965518 |
| Address1 | One World Trade Center |
| Address2 | Suite 8500 |
| All Time High | 86.55 |
| All Time Low | 0.015 |
| Ask | 28.97 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,113,800 |
| Average Daily Volume3 Month | 1,763,465 |
| Average Volume | 1,763,465 |
| Average Volume10Days | 2,113,800 |
| Beta | 2.558 |
| Bid | 18.85 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 3.364 |
| City | New York |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 23.18 |
| Current Ratio | 6.287 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 26.25 |
| Day Low | 22.5 |
| Debt To Equity | 12.211 |
| Display Name | Definium Therapeutics |
| Earnings Call Timestamp End | 1,772,139,600 |
| Earnings Call Timestamp Start | 1,772,139,600 |
| Earnings Timestamp | 1,772,139,600 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -166,282,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.667 |
| Enterprise Value | 1,939,988,608 |
| Eps Current Year | -1.9425 |
| Eps Forward | -1.72545 |
| Eps Trailing Twelve Months | -2.06 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.718 |
| Fifty Day Average Change | 4.462 |
| Fifty Day Average Change Percent | 0.23838016 |
| Fifty Two Week Change Percent | 299.65518 |
| Fifty Two Week High | 26.25 |
| Fifty Two Week High Change | -3.0699997 |
| Fifty Two Week High Change Percent | -0.11695237 |
| Fifty Two Week Low | 5.72 |
| Fifty Two Week Low Change | 17.460001 |
| Fifty Two Week Low Change Percent | 3.0524478 |
| Fifty Two Week Range | 5.72 - 26.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,479,220,200,000 |
| Float Shares | 93,687,329 |
| Forward Eps | -1.72545 |
| Forward P E | -13.434176 |
| Free Cashflow | -57,812,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 105 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.013940001 |
| Held Percent Institutions | 0.71815 |
| Implied Shares Outstanding | 99,698,129 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,661,731,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York. |
| Long Name | Definium Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,311,002,624 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_631045282 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -183,792,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,311,002,630 |
| Number Of Analyst Opinions | 15 |
| Open | 25.63 |
| Operating Cashflow | -131,560,000 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 212 220 6633 |
| Pre Market Change | 1.3199997 |
| Pre Market Change Percent | 5.694563 |
| Pre Market Price | 24.5 |
| Pre Market Time | 1,776,770,981 |
| Previous Close | 22.68 |
| Price Eps Current Year | -11.933076 |
| Price Hint | 2 |
| Price To Book | 6.8906064 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.171 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.5 |
| Regular Market Change Percent | 2.20459 |
| Regular Market Day High | 26.25 |
| Regular Market Day Low | 22.5 |
| Regular Market Day Range | 22.5 - 26.25 |
| Regular Market Open | 25.63 |
| Regular Market Previous Close | 22.68 |
| Regular Market Price | 23.18 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 5,720,777 |
| Return On Assets | -0.28008 |
| Return On Equity | -0.64064 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 99,698,129 |
| Shares Percent Shares Out | 0.1518 |
| Shares Short | 15,129,638 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 19,343,010 |
| Short Name | Definium Therapeutics, Inc. |
| Short Percent Of Float | 0.1527 |
| Short Ratio | 8.48 |
| Source Interval | 15 |
| State | NY |
| Symbol | DFTX |
| Target High Price | 70.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 36.66667 |
| Target Median Price | 32.0 |
| Total Cash | 411,592,992 |
| Total Cash Per Share | 4.128 |
| Total Debt | 40,579,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.4558 |
| Two Hundred Day Average Change | 9.7242 |
| Two Hundred Day Average Change Percent | 0.72267723 |
| Type Disp | Equity |
| Volume | 5,720,777 |
| Website | https://definiumtx.com |
| Zip | 10,007 |